The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
Parkinson's disease
Parkinson's disease psychosis scale
SASPAP
psychosis
screening questionnaire
self-administered
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
08
09
2023
received:
17
06
2023
accepted:
19
09
2023
medline:
1
12
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
Psychosis is a common manifestation of Parkinson's disease (PD), and a major source of caregiver burden, nursing home placement, and mortality. Psychosis symptoms are often not volunteered during the clinic visit because of embarrassment or lack of insight, and there is no validated screening scale. We compare a new self-administered psychosis screening questionnaire against the Parkinson's Disease Psychosis Scale (PDPS) and physician interview as the gold standard assessments. To create and validate the Self-Administered Screening Questionnaire for PD-Associated Psychosis (SASPAP). The questionnaire was developed through a modified Delphi method by a committee of two neurologists, a psychiatrist, a patient, and patient advocate and underwent several rounds of revisions, including patient β-testing. It was provided by staff at intake to 250 consecutive patients diagnosed with PD, at the Methodist Hospital Movement Disorders Clinic, and separately to their caregivers when available. Later, the PDPS and a general psychosis interview were administered by PD specialists without knowledge of the screening questionnaire responses. Two hundred and fifty consecutive patients with PD (mean age, 68.6 ± 7.0; mean age of PD onset, 62.7 ± 10.5 years; 35.2% female) were included. The screening questionnaire was positive for psychosis (any of the four questions positive) in 33.6% of patients. Compared to the gold standard, the SASPAP sensitivity was 87.8% and the specificity 92.3%. This four-question self-administered screening questionnaire for PD psychosis demonstrated high diagnostic accuracy compared with the gold standard assessments and can be self-completed at visit intake. © 2023 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
BACKGROUND
Psychosis is a common manifestation of Parkinson's disease (PD), and a major source of caregiver burden, nursing home placement, and mortality. Psychosis symptoms are often not volunteered during the clinic visit because of embarrassment or lack of insight, and there is no validated screening scale. We compare a new self-administered psychosis screening questionnaire against the Parkinson's Disease Psychosis Scale (PDPS) and physician interview as the gold standard assessments.
OBJECTIVE
OBJECTIVE
To create and validate the Self-Administered Screening Questionnaire for PD-Associated Psychosis (SASPAP).
METHODS
METHODS
The questionnaire was developed through a modified Delphi method by a committee of two neurologists, a psychiatrist, a patient, and patient advocate and underwent several rounds of revisions, including patient β-testing. It was provided by staff at intake to 250 consecutive patients diagnosed with PD, at the Methodist Hospital Movement Disorders Clinic, and separately to their caregivers when available. Later, the PDPS and a general psychosis interview were administered by PD specialists without knowledge of the screening questionnaire responses.
RESULTS
RESULTS
Two hundred and fifty consecutive patients with PD (mean age, 68.6 ± 7.0; mean age of PD onset, 62.7 ± 10.5 years; 35.2% female) were included. The screening questionnaire was positive for psychosis (any of the four questions positive) in 33.6% of patients. Compared to the gold standard, the SASPAP sensitivity was 87.8% and the specificity 92.3%.
CONCLUSION
CONCLUSIONS
This four-question self-administered screening questionnaire for PD psychosis demonstrated high diagnostic accuracy compared with the gold standard assessments and can be self-completed at visit intake. © 2023 International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1982-1987Subventions
Organisme : Unrestricted Educational Grant from ACADIA Pharmaceuticals
Informations de copyright
© 2023 International Parkinson and Movement Disorder Society.
Références
Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord 2006;15(Suppl 3):S38-S41. https://doi.org/10.1016/S1353-8020(09)70777-1
Ondo WG, Sarfaraz S, Lee M. A novel scale to assess psychosis in patients with Parkinson's disease. J Clin Mov Disord 2015;2:17. https://doi.org/10.1186/s40734-015-0024-5
Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an Ninds, Nimh Work Group. Mov Disord 2007;22:1061-1068. https://doi.org/10.1002/mds.21382
Fytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D. The psychosis Spectrum in Parkinson disease. Nat Rev Neurol 2017;13:81-95. https://doi.org/10.1038/nrneurol.2016.200
Goetz CG, Fan WQ, Leurgans S, Bernard B, Stebbins GT. The malignant course of benign hallucinations in Parkinson disease. Arch Neurol 2006;63:1-3. https://doi.org/10.1001/archneur.63.5.713
Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745. https://doi.org/10.1093/brain/123.4.733
Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:484-500. https://doi.org/10.1002/mds.21875
Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004;63:293-300. https://doi.org/10.1212/01.wnl.0000129843.15756.a3
Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov Disord 2013;28:755-762. https://doi.org/10.1002/mds.25389
Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761. https://doi.org/10.1212/01.wnl.0000068010.82167.cf
Factor SA, Steenland NK, Higgins DS, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Disord 2011;26:2190-2195. https://doi.org/10.1002/mds.23806
Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010;67:996-1001. https://doi.org/10.1001/archneurol.2010.166
Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005;20:1439-1448. https://doi.org/10.1002/mds.20582
Zhong M, Gu R, Zhu S, et al. Prevalence and risk factors for minor hallucinations in patients with Parkinson's disease. Behav Neurol 2021;3469706. https://doi.org/10.1155/2021/3469706
Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010;289:12-17. https://doi.org/10.1016/j.jns.2009.08.014